Cargando…
Looking beyond 28-day all-cause mortality
A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to t...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137308/ https://www.ncbi.nlm.nih.gov/pubmed/12225601 |
_version_ | 1782120428233293824 |
---|---|
author | Rubenfeld, Gordon |
author_facet | Rubenfeld, Gordon |
author_sort | Rubenfeld, Gordon |
collection | PubMed |
description | A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to treatments in the intensive care unit that will minimize the effects of critical illness on these sequelae. Although the study by Rublee and colleagues in this issue of Critical Care provides little clinically useful information about the effects of antithrombin III on quality of life, it provides some insight into the challenges that investigators will encounter as we try to incorporate these outcomes into studies of critical illness. |
format | Text |
id | pubmed-137308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1373082003-02-27 Looking beyond 28-day all-cause mortality Rubenfeld, Gordon Crit Care Commentary A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to treatments in the intensive care unit that will minimize the effects of critical illness on these sequelae. Although the study by Rublee and colleagues in this issue of Critical Care provides little clinically useful information about the effects of antithrombin III on quality of life, it provides some insight into the challenges that investigators will encounter as we try to incorporate these outcomes into studies of critical illness. BioMed Central 2002 2002-07-08 /pmc/articles/PMC137308/ /pubmed/12225601 Text en Copyright © 2002 BioMed Central Ltd |
spellingShingle | Commentary Rubenfeld, Gordon Looking beyond 28-day all-cause mortality |
title | Looking beyond 28-day all-cause mortality |
title_full | Looking beyond 28-day all-cause mortality |
title_fullStr | Looking beyond 28-day all-cause mortality |
title_full_unstemmed | Looking beyond 28-day all-cause mortality |
title_short | Looking beyond 28-day all-cause mortality |
title_sort | looking beyond 28-day all-cause mortality |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137308/ https://www.ncbi.nlm.nih.gov/pubmed/12225601 |
work_keys_str_mv | AT rubenfeldgordon lookingbeyond28dayallcausemortality |